NAVCO Pharmaceuticals Inc
NAV.V
Get informed when a big investor buys or sells
+ FollowMarket Cap$285.35K
Close$
Share Statistics
| Market cap | $285,348.00 |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 1.09 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About NAVCO Pharmaceuticals Inc
CEO: Geoffrey Lee Navco Pharmaceuticals, Inc. engages in the manufacture and research of nano-technology products and materials. It uses Computerized Nano-meter Algorithms. The company was founded by Marek Jasinski on April 21, 2018 and is headquartered in Burlington, Canada.